1-for-30 Reverse Split to Cut Shares to 3.3M and Secure Nasdaq Listing
Cue Biopharma will implement a 1-for-30 reverse stock split on April 23, 2026, reducing outstanding shares from 97.7 million to 3.3 million, regaining Nasdaq compliance. Trading begins April 24 under a new CUSIP, and options, warrants and incentive awards will adjust proportionately.
1. Reverse Stock Split Implementation
On April 23, 2026 at 5:00 p.m. Eastern Time, Cue Biopharma will execute a 1-for-30 reverse stock split, combining every 30 existing common shares into one new share. This corporate action reduces the company’s issued and outstanding shares from approximately 97.7 million to about 3.3 million.
2. Adjustment of Equity Instruments
All outstanding stock options, warrants and equity incentive plan awards will be adjusted proportionately under the split terms, increasing exercise prices by a factor of 30 while reducing the number of shares issuable upon exercise.
3. Fractional Share Treatment and Trading
No fractional shares will be issued; stockholders entitled to fractions will receive a cash payment instead. Split-adjusted shares will begin trading on April 24 under the existing ticker with a new CUSIP number 22978P205 on the Nasdaq Capital Market.